Bright Minds Biosciences (Bright Minds Biosciences) Total Payout Yield % : -14.10 (As of May. 21, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Bright Minds Biosciences's current Total Payout Yield % is -14.10%.

Bright Minds Biosciences Total Payout Yield % Historical Data

The historical data trend for Bright Minds Biosciences's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Total Payout Yield % Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Total Payout Yield %

-25.91

-13.98

-14.91

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Payout Yield %	Get a 7-Day Free Trial												-25.91	-	-	-	-42.05

Competitive Comparison of Bright Minds Biosciences's Total Payout Yield %

For the Biotechnology subindustry, Bright Minds Biosciences's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bright Minds Biosciences's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Total Payout Yield % falls into.

Bright Minds Biosciences Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Bright Minds Biosciences's Total Payout Yield % for the fiscal year that ended in Sep. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0.9	+	0)	/	6.035312
	=	-14.91%

Bright Minds Biosciences's annualized Total Payout Yield % for the quarter that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0.671	+	0)	*	4	/	6.3831482
	=	-42.05%

Bright Minds Biosciences Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Bright Minds Biosciences Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.